Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

NICE recommends Merck’s erbitux to treat R/M SCCHN in oral cavity

pharmaceutical-technologyAugust 11, 2017

Tag: Erbitux , NICE , R/M SCCHN

PharmaSources Customer Service